View All Conferences
American Society of Clinical Oncology 2017
Serge Verstovsek, MD on the Phase 2 Study Involving Ruxolitinib with Azacytidine
At the ASCO Meeting, Serge Verstovsek, MD of the MD Anderson Cancer Center discussed the combination of ruxolitinib and azacytidine in myelofibrosis treatment.
Overall Survival Improved in AML Patients by Gilteritinib
New data concludes that molecular responses to gilteritinib directly correlated with clinical response and improved overall survival (OS) in patients with FLT3 mutation-positive (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML).
Daniel DeAngelo, MD, PhD Discusses Acute Myeloid Leukemia
At the 2017 ASCO Annual Meeting, Rare Disease Report sat with Daniel DeAngelo, MD, PhD of the Dana Farber Cancer Institute to discuss acute myeloid leukemia.
Serge Verstovsek, MD Discusses Myelofibrosis and Thrombocytosis
Serge Verstovsek, MD of the MD Anderson Cancer Center sat down with RDR to discuss myelofibrosis, thrombocytosis, and potential treatment options for both.
Gerhard Zugmaier, MD Discusses Acute Lymphoblastic Leukemia
Gerhard Zugmaier, MD of Amgen and the University of Marburg sat down with RDR to discuss acute lymphoblastic leukemia.
The Angiosarcoma Project Aims to Create New DTP Approach for Identifying AS
Data concludes that a new DTP approach enabled identification of an initial cohort of angiosarcoma patients willing to share blood and medical records.
ASCO: Is Blincyto Safe and Effective in Pediatric Relapsed or Refractory ALL Patients?
At ASCO, data from an open-label, expanded access study involving children with relapsed/refractory B-precursor ALL was presented.
Ruben Mesa, MD Discusses Myelofibrosis
Ruben Mesa, MD of the Mayo Clinic sat down with RDR to discuss myelofibrosis, supportive care, and his study combining ruxolitinib and momelotinib.
ASCO: Testicular Cancer and Low Testosterone
38% of the 491 testicular cancer survivors had hypogonadism and had significantly higher incidence of high cholesterol, high blood pressure, erectile dysfunction, diabetes, and anxiety or depression
Enrica Marchi, MD Discusses Using Case Match Control in Orphan Diagnoses
Enrica Marci, MD of the Columbia University School of Medicine sat down with RDR to discuss her study with Owen O'Connor, presented at ASCO 2017.
Next Page >>
MOST POPULAR ARTICLES
FDA Approves Hydroxyurea Tablets for Pediatric Sickle Cell Anemia
Q&A with Hartmann Wellhoefer, Shire's VP and Head of Medical Affairs; Rare Diseases & Internal Medicine
FDA Approval Granted to CIDP Treatment
Syringomyelia: a Complex Disease Rarely Recognized in Medicine
STRATEGIC ALLIANCE PARTNERSHIP PROGRAM >
Familial Chylomicronemia Syndrome
MJH ASSOCIATES >
Specialty Pharmacy Times
Terms & Conditions
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.